Almost 200 million doses of medicine for the treatment of neglected diseases in Africa are at risk of expiring because of foreign aid budget cuts, the Telegraph has learnt.
Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced that the U.S. Food and Drug Administration (FDA) has approved Vermox chewable (mebendazole chewable 500mg tablets) for the treatment of patients one year of age and older with gastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm).
Janssen's Vermox (Mebendazole) Approved In US
Janssen Pharmaceuticals, a unit of Johnson & Johnson ($JNJ), has submitted a new drug application to the FDA for a 500-milligram chewable tablet targeting intestinal worms in children one year or older.nnThe new formulation of mebendazole is in response to the World Health Organization’s call for a more child-friendly version of the drug that can be chewed or can be mixed with water and swallowed, the company said. The current registered forms of the drug have been in use for more than 45 years.
Impax Laboratories has announced that Emverm (mebendazole) 100 mg chewable tablets are now available for healthcare providers to prescribe to patients in the US. Emverm is indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections.
Anvisa ordered the suspension of the drug MENTELMIN (mebendazole) 100 mg, tablet, the company Theodoro F. Sobral & Cia Ltda.nThe company, which had requested the Anvisa canceling the presentation of the drug in June 2013, informed the Agency's voluntary recall of lots that are still on the market.
Anvisa determined the suspension of the distribution, marketing and use of Mentelmin drug (mebendazole), 20 mg / ml, manufactured by Theodore F. Sobral Ltda.
Anvisa suspends drugs manufactured by Brainfarma
Millions To Be Made On...Generic Drugs?